P. Grootendorst

发表

Censoring in statistical models of health status: What happens when one can do better than ‘1’

P. Grootendorst, 2004, Quality of Life Research.

Does it matter whom and how you ask? inter- and intra-rater agreement in the Ontario Health Survey.

D. Feeny, W. Furlong, D. Feeny, 1997, Journal of clinical epidemiology.

Intended and unintended effects of restrictions on the sale of cigarillos to youth: evidence from Canada

P. Grootendorst, H. V. Nguyen, 2014, Tobacco Control.

Factors associated with mental health in Canadian Veterans

P. Coyte, P. Grootendorst, M. Rebeira, 2017 .

Health Utilities Index Mark 3

D. Feeny, W. Furlong, P. Grootendorst, 2016 .

Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada.

J. Hurley, R. Tamblyn, P. Grootendorst, 2005, Health economics.

Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

D. Coyle, G. Wells, P. Grootendorst, 2020, ClinicoEconomics and outcomes research : CEOR.

MANAGING PHARMACEUTICAL EXPENDITURE : AN OVERVIEW AND OPTIONS FOR CANADA FEBRUARY 2011

P. Grootendorst, 2011 .

Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study

N. Mitsakakis, A. Chit, P. Grootendorst, 2020, Vaccine: X.

Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents

S. Schneeweiss, S. Soumerai, M. Maclure, 2004, Medical care.

Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence

J. Lexchin, P. Grootendorst, 2004, International journal of health services : planning, administration, evaluation.

Reference-based pricing (RBP) of prescription drugs.

P Grootendorst, B. O'brien, A. Holbrook, 1997, The Canadian journal of cardiology.

Evaluating the impact of reference-based pricing.

A. Holbrook, P. Grootendorst, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Estimating the clinical cost of drug development for orphan versus non-orphan drugs

M. Mamdani, A. Hollis, P. Grootendorst, 2019, Orphanet Journal of Rare Diseases.

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

B. O'brien, A. Levy, A. Holbrook, 2005, Health services research.

Economic evaluation of vaccines in Canada: A systematic review

Jianhong Wu, A. Chit, J. Langley, 2016, Human vaccines & immunotherapeutics.

Proportion of osteoporotic post‐menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy

P. Grootendorst, M. Levine, 2000, Pharmacoepidemiology and drug safety.

Cost analysis of dialysis treatments for end-stage renal disease (ESRD).

R. Goeree, D. Churchill, P. Grootendorst, 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey.

D. Feeny, W. Furlong, D. Feeny, 2000, Medical care.

Effect of copayments on drug use in the presence of annual payment limits.

J. Hoar, P. Grootendorst, G. Kephart, 2007, The American journal of managed care.

Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature

P. Grootendorst, Emmanuelle Piérard, Minsup Shim, 2007, Expert review of pharmacoeconomics & outcomes research.

Instrumental Variables: Informing Policy

P. Grootendorst, M. Auld, 2014 .

Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study

A. Burchell, S. Rourke, P. Grootendorst, 2015, PloS one.

Health Utilities Index Mark 3

D. Feeny, W. Furlong, P. Grootendorst, 2016 .

Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update

P. Grootendorst, M. Krahn, J. Feld, 2015, BMJ Open.

Economic instruments for obesity prevention: results of a scoping review and modified delphi survey

A. Drewnowski, S. Cash, I. Janssen, 2011, The international journal of behavioral nutrition and physical activity.

Disclosure of Physician Prescribing Information and Prescription Drug Costs: Evidence from Saskatchewan

P. Grootendorst, 2005 .

The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach

P. Grootendorst, M. Krahn, J. Feld, 2020, Liver international : official journal of the International Association for the Study of the Liver.

The effect of patented drug price on the share of new medicines across OECD countries.

P. Grootendorst, Oliver Spicer, 2022, Health policy.

Determinants of chronic physical health conditions in Canadian Veterans

P. Coyte, P. Grootendorst, 2015 .

Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.

P. Grootendorst, 2002, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report

B. O'brien, A. Levy, A. Holbrook, 2002 .

How Effective Is the Medicare Part D Drug Plan?

P. Grootendorst, 2015, Annals of Internal Medicine.

Impact of Antibiotic Administrative Restrictions on Trends in Antibiotic Resistance

S. Macleod, P. Grootendorst, D. Low, 2006, Canadian journal of public health = Revue canadienne de sante publique.

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology

M. Mamdani, P. Grootendorst, M. Krahn, 2017, PharmacoEconomics - Open.

Financial burden of household out-of-pocket expenditures for prescription drugs: Cross-sectional analysis based on national survey data

P. Grootendorst, B. Bereza, L. McLeod, 2011, Open medicine : a peer-reviewed, independent, open-access journal.

Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?

M. Veall, P. Grootendorst, 2003 .

Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review

P. Grootendorst, A. Burden, S. Cadarette, 2022, Osteoporosis International.

The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.

F. Lichtenberg, P. Grootendorst, P. Lefebvre, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Newton’s First Law as Applied to Pharmacies: Why Entry Order Matters for Generics

A. Hollis, P. Grootendorst, Ali Shajarizadeh, 2015 .

Pharmacy location and medical need: regional evidence from Canada

P. Grootendorst, 2022, BMC Health Services Research.

Clinical and microbiological epidemiology of early and late infectious complications among solid‐organ transplant recipients requiring hospitalization

P. Grootendorst, B. Hamandi, E. Papadimitropoulos, 2016, Transplant international : official journal of the European Society for Organ Transplantation.

The case for an essential medicines list for Canada

P. Grootendorst, J. Duffin, G. Eom, 2016, Canadian Medical Association Journal.

Federal Patent Extension, Provincial Policies, and Drug Expenditures, 1975-2000

P. Grootendorst, L. D. Matteo, 2002 .

The cost of drug development: a systematic review.

Joel Lexchin, Devon L. Greyson, Devon Greyson, 2011, Health policy.

Equity in dental care among Canadian households

P. Grootendorst, C. Quiñonez, 2011, International journal for equity in health.

A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study

Peter C Austin, Paul Grootendorst, P. Austin, 2007, Statistics in medicine.

Dental insurance, income and the use of dental care in Canada.

P. Grootendorst, T. Bhatti, Z. Rana, 2007, Journal.

Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.

Paul Grootendorst, Bernie J O'Brien, Adrian R Levy, 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.

P. Grootendorst, M. Abbaspour, X. Wu, 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis

T. Einarson, D. Juurlink, P. Grootendorst, 2011, Pharmacoepidemiology and drug safety.

Estimating chronic hepatitis C prognosis using transient elastography‐based liver stiffness: A systematic review and meta‐analysis

P. Grootendorst, M. Krahn, J. Feld, 2018, Journal of viral hepatitis.

Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in England

N. Mitsakakis, A. Chit, P. Grootendorst, 2020, JAMA network open.

An empirical analysis of milk addiction.

Paul Grootendorst, P. Grootendorst, M. Auld, 2004, Journal of health economics.

Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice

P. Grootendorst, K. Pang, I. D. de Lannoy, 2021, Biopharmaceutics & drug disposition.

Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments.

R. Goeree, A. Willan, P. Grootendorst, 2015, Annals of emergency medicine.

Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study

Peter C Austin, Sharon-Lise T Normand, Paul Grootendorst, 2007, Statistics in medicine.

The Impact of Tiered-Pricing Framework on Generic Entry in Canada

L. Lynd, A. Anis, A. Hollis, 2020, International journal of health policy and management.

A comparison of mechanisms for setting generic drug prices in Canada

A. Hollis, P. Grootendorst, 2017 .

Challenges for Causal Inference in Obesity Research

P. Grootendorst, M. Auld, 2011 .

Becoming the best mom that I can: women's experiences of managing depression during pregnancy – a qualitative study

H. Boon, P. Grootendorst, S. Romans, 2007, BMC women's health.

Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare

B. O'brien, J. Hurley, P. Grootendorst, 1996 .

The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.

E. Rahme, M. Maclure, D. Marshall, 2007, Health Policy.

The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada.

P. Grootendorst, L. D. Matteo, 2007, Healthcare policy = Politiques de sante.

Prescription Drug Insurance and Reimbursement

P. Grootendorst, 2006 .

A Review of the Comprehensiveness of Provincial Drug Coverage for Canadian Seniors*

J. Hurley, P. Grootendorst, D. Willison, 2003, Canadian Journal on Aging / La Revue canadienne du vieillissement.

The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada.

Thomas F. Crossley, Sule Alan, M. Veall, 2002, Journal of health economics.

Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population

M. Levine, P. Grootendorst, 2002 .

Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs

Thomas F. Crossley, Sule Alan, M. Veall, 2003, SSRN Electronic Journal.

Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis

S. Macleod, P. Grootendorst, D. Marshall, 2006, Journal of health services research & policy.

Factors associated with drug shortages in Canada: a retrospective cohort study.

L. Lynd, A. Anis, A. Hollis, 2020, CMAJ open.

Canadian Agency for Drugs and Technologies in Heath Liquid-Based Techniques for Cervical Cancer Screening : Systematic Review and Cost-Effectiveness Analysis

G. Tomlinson, A. Tricco, H. Witteman, 2008 .

Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada

P. Grootendorst, Emmanuelle Piérard, 2014 .

Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study

S. Rourke, J. Cairney, P. Grootendorst, 2018, PloS one.

Canada’s laws on pharmaceutical intellectual property: the case for fundamental reform

Ron A. Bouchard, A. Hollis, P. Grootendorst, 2012, Canadian Medical Association Journal.

On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective.

S. Schneeweiss, S. Soumerai, M. Maclure, 2001, Health policy.

How should we support pharmaceutical innovation?

Paul Grootendorst, P. Grootendorst, 2009, Expert review of pharmacoeconomics & outcomes research.

Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?

P. Grootendorst, 2009 .

Lessons from 20 years of medical cannabis use in Canada

P. Grootendorst, Minsup Shim, Hai V Nguyen, 2023, PloS one.

Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries

Jeremy M. Grimshaw, Paul Babyn, Kathy Boutis, 2013, Canadian Medical Association Journal.

The 2011 Canada-European Union Comprehensive Economic and Trade Agreement: an economic impact assessment of the EU’s proposed pharmaceutical intellectual property provisions

A. Hollis, P. Grootendorst, 2011 .

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

B. O'brien, A. Levy, A. Holbrook, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.

A R Levy, B. O'brien, A. Levy, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.

P. Grootendorst, D. Stewart, 2006, Health economics.

Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research

P Gustafson, K M Johnston, A R Levy, 2008, Statistics in medicine.

Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario

J. Lexchin, P. Grootendorst, Minsup Shim, 2018, International journal of health services : planning, administration, evaluation.

Comparison of Fracture Identification Using Different Definitions in Healthcare Administrative (Claims) Data

A. Cheung, P. Grootendorst, S. Cadarette, 2023, Pharmacy.

New approaches to rewarding pharmaceutical innovation

A. Hollis, P. Grootendorst, Thomas Pogge, 2011, Canadian Medical Association Journal.

The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs

B. O'brien, A. Levy, A. Holbrook, 2004 .

A comparison of alternative models of prescription drug utilization.

P. Grootendorst, P V Grootendorst, 1995, Health economics.

Implementation of the appointment-based model in community pharmacies: An analysis of refills and adherence.

P. Grootendorst, L. Dolovich, A. Mathers, 2023, Research in Social and Administrative Pharmacy.

The Opportunity Cost of Capital

A. Chit, P. Grootendorst, M. Krahn, 2015, Inquiry : a journal of medical care organization, provision and financing.

Patents and Other Incentives for Pharmaceutical Innovation

A. Hollis, P. Grootendorst, A. Edwards, 2014 .

Patent Medicine? Alternative incentive mechanisms to promote drug discovery.

P. Grootendorst, J. Biggs, David K. Levine, 2011 .

Validation of a prediction model to estimate health utilities index Mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip.

D. Feeny, N. Bellamy, G. Torrance, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee.

David Feeny, Nicholas Bellamy, Deborah Marshall, 2007, The Journal of rheumatology.

PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

D. Feeny, N. Bellamy, G. Torrance, 2005 .

Health care policy evaluation using longitudinal insurance claims data: an application of the panel Tobit estimator.

P. Grootendorst, 1997, Health economics.

Does rising income inequality affect mortality rates in advanced economies?

P. Coyte, Victor Aguirregabiria, P. Grootendorst, 2017 .

Impact of a peer comparison intervention on seasonal influenza vaccine uptake in community pharmacy: A national cluster randomized study.

N. Mitsakakis, A. Chit, P. Grootendorst, 2021, Journal of the American Pharmacists Association : JAPhA.

A Program for Research on Social and Economic Dimensions of an Aging Population Patents, Public-private Partnerships or Prizes: How Should We Support Pharmaceutical Innovation? Patents, Public-private Partnerships or Prizes: How Should We Support Pharmaceutical Innovation? Patents, Public-private Pa

P. Pennefather, A. Hollis, P. Grootendorst, 2022 .

A review of instrumental variables estimation in the applied health sciences

P. Grootendorst, 2007 .

Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update

P. Grootendorst, M. Krahn, J. Feld, 2019, BMJ Open.

The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs

B. O'brien, A. Levy, A. Holbrook, 2004 .

Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

D. Coyle, G. Wells, P. Grootendorst, 2020 .

Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

D. Coyle, G. Wells, P. Grootendorst, 2020 .

The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature

P. Grootendorst, Emmanuelle Piérard, Minsup Shim, 2007 .

Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey

W. Furlong, P. Grootendorst, D. Feeney, 1999 .

Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.

P. Grootendorst, M. Abbaspour, X. Wu, 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

A review of instrumental variables estimation of treatment effects in the applied health sciences

Paul Grootendorst, P. Grootendorst, 2007, Health Services and Outcomes Research Methodology.

Canada’s laws on pharmaceutical intellectual property: the case for fundamental reform

Ron A. Bouchard, A. Hollis, P. Grootendorst, 2012, Canadian Medical Association Journal.

How should we support pharmaceutical innovation?

P. Grootendorst, 2009, Expert review of pharmacoeconomics & outcomes research.

The Economics of Cross-Border Trade in Pharmaceuticals: Theory and Evidence

P. Grootendorst, 2004 .

Policy to encourage the development of antimicrobials

A. Chit, P. Grootendorst, 2018 .

Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis.

C. de Oliveira, P. Grootendorst, H. Wijeysundera, 2013, CMAJ open.